Officer/Director Files Intent to Sell $9.2M in GeneDx Holdings Stock
WGS sits 78% above its 52-week low of $55.17.
Summary
Katherine Stueland, an Officer and Director of GeneDx Holdings Corp., filed a Form 144 indicating intent to sell approximately $9.2 million worth of Class A Common Stock, primarily related to the vesting of restricted stock units.
Key Events · Ownership and Investor Activity · WGS
-
Proposed Stock Sale
Katherine Stueland, an Officer and Director, intends to sell 94,495 shares of Class A Common Stock.
-
Approximate Value
The proposed sale has an approximate market value of $9,268,700.
-
Reason for Sale
The shares are primarily being sold in connection with the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) over the coming months.
Analysis · WGS · Industrial Applications And Services
This Form 144 filing indicates that Katherine Stueland, an Officer and Director at GeneDx Holdings Corp., plans to sell a substantial amount of company stock, valued at approximately $9.2 million. While the dollar amount is significant, the filing specifies that these sales are primarily tied to the vesting of restricted stock units and performance-based restricted stock units over the coming months. Such sales are often pre-planned and compensation-related, rather than a discretionary signal of a change in outlook on the company's fundamentals. However, any large insider sale, even for routine reasons, can contribute to market overhang.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WGS was trading at $98.17 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $55.17 to $170.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.